Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Virginia Commonwealth University Abbott |
---|---|
Information provided by: | Virginia Commonwealth University |
ClinicalTrials.gov Identifier: | NCT00318929 |
There is a bimodal distribution to the new onset seizures with one peak occurring in the very young and the second peak occurring in persons over age 65 years. The presentation of seizures in the elderly may vary from that of younger patients and the diagnosis may be confused with other conditions such as transient ischemic attacks. However, the consequences of epilepsy in the elderly can be severe leading to impaired cognition, increased falls, and a decreased quality of life. The treatment of epilepsy may be complicated by pharmacokinetic and pharmacodynamic changes occurring in the elderly.
Condition | Intervention |
---|---|
Elderly Epilepsy Seizures |
Drug: Divalproex Sodium Extended-Release Tablets |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Official Title: | Tolerability and Efficacy of Depakote-ER in the Elderly |
Estimated Enrollment: | 20 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | September 2008 |
There is a bimodal distribution to the new onset seizures with one peak occurring in the very young and the second peak occurring in persons over age 65 years. The presentation of seizures in the elderly may vary from that of younger patients and the diagnosis may be confused with other conditions such as transient ischemic attacks. However, the consequences of epilepsy in the elderly can be severe leading to impaired cognition, increased falls, and a decreased quality of life. The treatment of epilepsy may be complicated by pharmacokinetic and pharmacodynamic changes occurring in the elderly.
Three Veterans Cooperative trials evaluating antiepileptic drug (AED) therapy in the elderly demonstrated that the ability to tolerate the AED is a more determining factor for long term success than the ability to suppress seizure activity. In general, elderly patients appear more intolerable to medications. This may stem from co-morbid conditions, concurrent medications, pharmacokinetic changes, and/or pharmacodynamic changes. Therefore, it is important to study the efficacy and tolerability of AEDs in the elderly.
Valproic acid has been available for the treatment of partial and generalized seizures since 1978. Sodium divalproex is metabolized in the gut to valproic acid. Depakote and Depakote-ER are among the dosage forms of sodium divalproex. Depakote is an enteric coated tablet that is designed to dissolve in the more alkaline milieu of the small intestine rather than the more acidic milieu of the stomach. This helps the drug to bypass the stomach and reduces gastrointestinal distress. Once the enteric coating dissolves, the sodium divalproex is metabolized to valproic acid and rapidly absorbed.
Depakote is administered twice a day. Depakote-ER is a controlled release drug delivery system designed to release drug over a 22 hour period which allows for once a day dosing. The efficacy and tolerability of Depakote-ER has not been described in elderly patients with epilepsy.
Ages Eligible for Study: | 60 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Has one of the following
Exclusion Criteria:
Contact: Alan R Towne, M.D. | 804-828-9940 | llbenson@vcu.edu |
Contact: William Garnett, Pharm.D. | 804-828-9940 |
United States, Virginia | |
Virginia Commonwealth University Medical Center, Department of Neurology | Recruiting |
Richmond, Virginia, United States, 23219 | |
Sub-Investigator: William Garnett, Pharm.D. | |
Sub-Investigator: Elizabeth Waterhouse, M.D. | |
Sub-Investigator: Jonathan Bekenstein, M.D. | |
Sub-Investigator: Evren Burakazi, MD | |
Principal Investigator: Alan Towne, M.D. |
Principal Investigator: | Alan R Towne, M.D. | Virginia Commonwealth University |
Responsible Party: | Virginia Commonwealth University ( Alan R. Towne, MD ) |
Study ID Numbers: | VCUHM10204 |
Study First Received: | April 25, 2006 |
Last Updated: | December 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00318929 History of Changes |
Health Authority: | United States: Institutional Review Board |
Treatment Efficacy pharmacokinetics |
Neurotransmitter Agents Tranquilizing Agents Epilepsy Seizures Psychotropic Drugs Central Nervous System Depressants |
Central Nervous System Diseases Antimanic Agents Brain Diseases Valproic Acid Anticonvulsants |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Diseases Central Nervous System Depressants Enzyme Inhibitors |
Brain Diseases Antimanic Agents Valproic Acid Pharmacologic Actions Epilepsy Therapeutic Uses GABA Agents Central Nervous System Agents Anticonvulsants |